Financial Performance - The company's operating revenue for Q3 2022 was ¥260,021,349.63, representing a year-on-year increase of 38.82%[7] - The net profit attributable to shareholders for Q3 2022 was ¥69,655,865.01, reflecting a year-on-year growth of 37.83%[7] - The basic earnings per share for Q3 2022 was ¥0.17, an increase of 41.67% compared to the same period last year[10] - Total operating revenue for the first three quarters of 2022 reached CNY 768,958,001.67, an increase of 30.5% compared to CNY 589,084,976.50 in the same period of 2021[32] - Net profit attributable to shareholders of the parent company for Q3 2022 was CNY 186,394,420.44, up 39.5% from CNY 133,515,911.70 in Q3 2021[35] - The total comprehensive income for the period attributable to the parent company's owners was CNY 188,603,697.10, an increase from CNY 133,300,185.61 in the previous year, representing a growth of approximately 41.5%[37] - Basic and diluted earnings per share increased to CNY 0.46 from CNY 0.33, reflecting a growth of 39.4% year-over-year[37] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,857,293,118.46, up 7.89% from the end of the previous year[10] - The company's total assets amounted to approximately CNY 1,857.29 million, an increase from CNY 1,721.43 million at the end of 2021, representing a growth of about 7.9%[24] - The total equity attributable to shareholders at the end of the reporting period was ¥1,642,930,238.61, up 9.07% from the previous year[10] - The company's total equity attributable to shareholders reached CNY 1,642,930,238.61, an increase from CNY 1,506,246,880.11 year-over-year[32] - Total liabilities as of Q3 2022 were CNY 210,268,274.55, a slight decrease from CNY 213,436,966.01 in the previous period[30] - The company's total liabilities included accounts payable of CNY 105.84 million, down from CNY 137.28 million, showing a decrease of approximately 22.8%[28] Cash Flow - The cash flow from operating activities for the year-to-date was ¥88,594,249.86, showing a decline of 44.81% compared to the previous year[10] - Cash inflow from operating activities totaled CNY 819,812,216.76, compared to CNY 667,239,103.01 in the same period last year, marking a rise of about 22.8%[41] - Cash outflow from operating activities was CNY 731,217,966.90, up from CNY 506,725,697.67, indicating an increase of approximately 44.3%[41] - The net cash flow from operating activities decreased to CNY 88,594,249.86 from CNY 160,513,405.34, a decline of about 44.8%[41] - The cash and cash equivalents at the end of the period stood at CNY 316,906,109.49, down from CNY 502,167,844.70, a decrease of approximately 37%[42] Expenses and Investments - Research and development expenses increased by 98.93% in the reporting period, indicating a significant investment in innovation[16] - Research and development expenses for Q3 2022 amounted to CNY 81,190,273.96, representing a 99.5% increase from CNY 40,813,549.75 in Q3 2021[32] - The total cost of operations for the first three quarters of 2022 was CNY 555,659,730.70, up 25.7% from CNY 441,748,005.59 in the same period of 2021[32] - The company has made significant investments in intangible assets, which increased to CNY 123.22 million from CNY 40.42 million, reflecting a growth of approximately 204.5%[27] Other Financial Metrics - The weighted average return on equity for Q3 2022 was 4.68%, an increase of 1.20 percentage points year-on-year[10] - The company reported a significant increase in unappropriated profits, reaching CNY 672,144,286.48, compared to CNY 537,879,866.04 in the previous year[32] - Deferred income tax liabilities remained stable at CNY 1,918,301.80, indicating consistent tax planning strategies[30] - The company reported a tax refund of CNY 60,268,772.37, slightly down from CNY 61,637,626.09 in the previous year[41] Shareholder Relations - The company is actively monitoring shareholder relationships, with notable connections among major shareholders, which may influence future strategic decisions[23]

Financial Performance - The company reported a total revenue of RMB 100 million for the first half of 2022, representing a year-on-year increase of 20%[19] - The net profit attributable to shareholders was RMB 15 million, up 25% compared to the same period last year[19] - The company's operating revenue for the first half of the year reached ¥508.94 million, representing a 26.67% increase compared to ¥401.77 million in the same period last year[24] - Net profit attributable to shareholders was ¥116.74 million, up 40.69% from ¥82.98 million year-on-year[24] - The net profit after deducting non-recurring gains and losses was ¥112.96 million, reflecting a 43.92% increase from ¥78.49 million in the previous year[24] - The company achieved a revenue of ¥509 million in the first half of 2022, representing a growth of 26.67% year-on-year, and a net profit of ¥117 million, up 40.69% year-on-year[49] - Basic earnings per share for the first half of 2022 was CNY 0.29, compared to CNY 0.21 in the same period of 2021, an increase of 38.1%[175] - The total comprehensive income for the first half of 2022 was CNY 117,214,779.35, compared to CNY 82,759,305.16 in the previous year, marking an increase of 41.6%[175] Research and Development - The company is investing RMB 10 million in R&D for new product development, focusing on innovative drug formulations[19] - The company invested ¥55.5 million in R&D during the reporting period, a year-on-year increase of 98.47%, with 24 products currently in the R&D stage[51] - The company has six engineering technology innovation platforms focused on small molecule drugs, peptide drugs, and oligonucleotide drugs[42] - The company has formed long-term partnerships with universities and research institutions to develop high-end pharmaceutical intermediates and raw materials[45] - The company applied for 7 new invention patents and was granted 5 new effective invention patents during the reporting period, bringing the total to 82 applied and 31 granted effective invention patents[54] - The company has implemented risk control measures to enhance R&D project success rates by increasing investment and improving project management[75] Market Expansion - The company has expanded its user base by 30%, reaching a total of 500,000 active users[19] - Market expansion efforts have led to a 40% increase in sales in the Southeast Asian region[19] - The company is actively expanding its overseas market presence, particularly in the U.S. generic drug market[50] - The company is exploring potential mergers and acquisitions to enhance its market position and product offerings[19] - The company is focused on developing new products and expanding its market presence, leveraging its industry experience to enhance trade operations and customer service[36] Financial Position - The total assets at the end of the reporting period were ¥1.78 billion, an increase of 3.58% from ¥1.72 billion at the end of the previous year[24] - The company's total assets measured at fair value reached 67.32 million, with 10.02 million in trading financial assets and 55.30 million in other equity investments[65] - The company's intangible assets increased to 124.02 million, a 206.82% rise from 40.42 million, primarily due to the acquisition of land use rights for the Cangshan project[60] - The company's total liabilities decreased to CNY 206,972,040.34 from CNY 213,436,966.01, reflecting a decline of about 3.0%[166] - Shareholders' equity increased to ¥1,576,039,684.78 from ¥1,507,996,366.78, showing an increase of approximately 4.5%[166] Environmental Compliance - The company reported a wastewater discharge of 9,465 tons and a COD discharge of 2.84 tons, with actual discharges being 2,320.9 tons and 0.1257 tons respectively[87] - VOCs emissions were recorded at 36.58 tons, with actual emissions at 0.7998 tons, indicating compliance with environmental standards[87] - The company has established a comprehensive environmental risk emergency mechanism, with emergency response plans filed with local environmental authorities[100] - The company has implemented online monitoring systems for wastewater and VOC emissions, ensuring real-time compliance tracking[103] - The company has no reported administrative penalties related to environmental issues during the reporting period[108] Shareholder Commitments - The controlling shareholder, Zhejiang Tongben Investment Co., Ltd., has committed to a share lock-up period from September 21, 2020, to September 20, 2023, and has complied with this commitment[111] - Shareholder Tiantai Borong has also committed to a share lock-up period from September 21, 2020, to September 20, 2023, and has adhered to this commitment[115] - The company has committed to maintaining compliance with relevant laws and regulations regarding share transfers and lock-up periods[120] - Major shareholders have pledged not to reduce their holdings during the lock-up period and will adhere to specific conditions for any future sales, including a minimum sale price not lower than the issuance price[125] - The company will publicly disclose any failure to meet shareholding commitments and will apologize to shareholders if such events occur[124]

Financial Performance - The company's operating revenue for 2021 was RMB 803,362,668.37, an increase of 11.36% compared to RMB 721,440,229.88 in 2020[30]. - The net profit attributable to shareholders for 2021 was RMB 168,713,891.23, reflecting a growth of 7.31% from RMB 157,227,222.39 in the previous year[30]. - The company achieved a total revenue of 803,362,668.37 CNY in 2021, representing a year-on-year growth of 11.36%[80]. - The net profit attributable to shareholders was 16,871.39 CNY, an increase of 7.31% compared to the previous year[80]. - The company's total revenue for 2021 reached RMB 800,459,806.62, representing an increase of 11.52% compared to the previous year[88]. - The gross profit margin improved slightly to 49.12%, an increase of 1.82 percentage points year-on-year[88]. - The company reported a revenue increase of 15% year-over-year, reaching $500 million in Q2 2021[184]. - The company provided a forward guidance of 10% revenue growth for the next quarter, projecting $550 million in revenue[184]. Dividend and Share Capital - The company plans to distribute a cash dividend of RMB 1.30 per 10 shares, totaling RMB 52,130,000 based on a total share capital of 401,000,000 shares as of December 31, 2021[8]. - The company does not plan to issue bonus shares or convert capital reserves into share capital for the 2021 fiscal year[8]. - The company's total share capital as of the end of 2021 was 401 million shares[8]. Risks and Challenges - The company reported no significant risks that could materially affect its operations during the reporting period[10]. - The company faced challenges such as fluctuations in the RMB exchange rate and rising costs of raw materials and international shipping[38]. - The company experienced a foreign exchange loss of 7.4356 million yuan in 2021, impacting net profit due to fluctuations in the RMB/USD exchange rate[156]. - The company faces risks from changes in the international trade environment, with 95% of its revenue coming from overseas sales, which may be impacted by trade protectionism[154]. - Environmental protection and safety production risks are present due to the nature of the chemical synthesis processes involved in API production, requiring compliance with national standards[155]. Research and Development - Research and development expenses totaled 69.35 million yuan, a year-on-year increase of 46.45%, with 23 products currently in the R&D phase[48]. - The company has established six engineering technology innovation platforms focused on various drug development areas, enhancing its R&D capabilities[73]. - The company has a total of 6 R&D centers and employs 189 R&D personnel, accounting for 15.66% of total employees[118]. - R&D investment for the reporting period was CNY 69.35 million, representing 8.63% of revenue, with a year-on-year growth of 46.45%[125]. - The company is developing several new drug projects, including a COVID-19 treatment and a GLP-1 receptor agonist for diabetes management, currently in various stages of development[119]. - The company has received multiple GMP certifications for its raw materials, including Abiraterone Acetate and Pregnenolone, enhancing its production capabilities[121]. Market and Sales - Sales of the core product, Dydrogesterone, continued to grow, with the company being one of the few globally capable of commercial production of Dydrogesterone raw materials[40]. - Domestic sales grew by 42.50% year-on-year, with collaborations established with leading domestic pharmaceutical companies[44]. - The company is actively expanding its domestic market presence, collaborating with leading domestic enterprises for multi-product cooperation[78]. - The marketing strategy focuses on customer-centric approaches, expanding market share in Europe, America, and Asia while collaborating with domestic formulation companies[150]. Investments and Acquisitions - The company invested approximately 500 million yuan in the construction of a new facility in Yangzhou, which includes multiple production workshops and a pilot testing center[45]. - The company acquired a 51.03% stake in Guangdong Zhuotai Pharmaceutical for 51 million yuan, focusing on synthetic biology research and applications[49]. - The company invested RMB 15 million to acquire a 10% stake in Yuandao Pharmaceutical (Suzhou) Co., Ltd., marking its entry into the innovative drug sector[55]. - The company completed an investment of RMB 51.03 million for a 51.03% stake in Guangdong Zhuotai Pharmaceutical Co., Ltd. during the reporting period[136]. Management and Governance - The total pre-tax remuneration received by directors and senior management during the reporting period amounts to 1,233.31 million yuan[180]. - The company has appointed directors and senior management personnel with extensive experience in various industries, including pharmaceuticals and international trade[188]. - The company’s board of directors has been consistent in its governance, with meetings held regularly to review financial reports and strategic decisions[191]. - The company has not reported any changes in shareholding for the directors and senior management during the reporting period[180]. Operational Efficiency - The company aims to reduce operational costs by 5% through process optimization initiatives[182]. - The company has reduced operational costs by 5%, resulting in improved profit margins[184]. - The company is focusing on technological innovation and product development to enhance competitiveness in the raw material drug industry[141]. Future Outlook - The company provided guidance for the next fiscal year, expecting revenue to grow by 10% to $1.65 billion[182]. - The company plans to establish a research and production platform for small molecule drugs, peptides, RNA drugs, and innovative drugs, expanding from APIs to formulations[145]. - The company intends to build new production capacity, including a project for 308 tons of specialty APIs and a production line for 200 million oncology formulations, expected to be completed by December 2024[149].

Financial Performance - The company's revenue for Q1 2022 was ¥218,833,057.33, representing a year-over-year increase of 17.45%[6] - Net profit attributable to shareholders was ¥40,852,669.98, an increase of 25.42% compared to the same period last year[6] - The net profit after deducting non-recurring gains and losses was ¥38,647,473.31, reflecting a growth of 42.66% year-over-year[6] - The basic earnings per share for the quarter was ¥0.10, up by 25.00% from the previous year[6] - Total operating revenue for Q1 2022 reached RMB 218,833,057.33, an increase of 17.4% compared to RMB 186,327,671.01 in Q1 2021[33] - Net profit for Q1 2022 was RMB 40,535,906.17, representing a 24.5% increase from RMB 32,573,374.77 in Q1 2021[35] - The company reported a total profit of RMB 53,376,879.48 for Q1 2022, compared to RMB 40,174,072.47 in Q1 2021, marking a growth of 32.5%[35] - The total comprehensive income for Q1 2022 was RMB 40,259,023.99, compared to RMB 32,573,374.77 in Q1 2021, reflecting an increase of 23.7%[35] Assets and Liabilities - The company's total assets at the end of the quarter were ¥1,730,843,194.07, a slight increase of 0.55% from the end of the previous year[9] - As of March 31, 2022, the company's total assets amounted to approximately RMB 1.73 billion, a slight increase from RMB 1.72 billion at the end of 2021[24] - The company's current assets totaled approximately RMB 941.28 million, compared to RMB 939.80 million in the previous year, indicating a marginal growth[24] - The company's total liabilities decreased to approximately RMB 180.85 million from RMB 213.44 million, a reduction of about 15.3%[28] - The equity attributable to shareholders increased to approximately RMB 1.55 billion from RMB 1.51 billion, showing a growth of about 2.5%[28] Cash Flow - Cash flow from operating activities was ¥25,379,011.24, up by 7.84% due to increased cash receipts from sales[17] - Cash inflow from operating activities totaled RMB 256,057,499.13 in Q1 2022, an increase from RMB 196,681,955.86 in Q1 2021[39] - The net cash flow from operating activities was $25,379,011.24, an increase from $23,534,564.69 in the previous period, indicating a growth of approximately 7.8%[41] - The total cash outflow from investing activities was $51,078,921.30, a decrease from $81,367,366.02, reflecting a reduction of about 37.1%[41] - The net cash flow from investing activities was -$50,998,162.80, showing an improvement compared to -$81,280,272.02 in the prior period[41] - Cash inflow from financing activities amounted to $3,460,000.00, while cash outflow was $1,132,075.48, resulting in a net cash flow from financing activities of $3,460,000.00[41] - The ending balance of cash and cash equivalents was $417,751,109.87, down from $497,284,564.09, reflecting a decrease of approximately 16%[41] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 19,637[18] - The largest shareholder, Zhejiang Tongben Investment Co., Ltd., held 38.30% of the shares, totaling 153,583,200 shares[18] Research and Development - Research and development expenses surged by 176.29%, indicating a significant increase in investment in innovation[17] - Research and development expenses surged to RMB 32,181,663.57 in Q1 2022, compared to RMB 11,647,603.71 in Q1 2021, reflecting a growth of 176.5%[33] Other Financial Metrics - The weighted average return on equity increased by 0.36 percentage points to 2.68%[9] - Tax expenses for Q1 2022 were RMB 12,840,973.31, up from RMB 7,600,697.70 in Q1 2021, indicating a rise of 68.8%[35] - The company recorded other income of RMB 800.59 in Q1 2022, down from RMB 2,052.00 in Q1 2021[35] - The company has not adopted the new accounting standards for the current year, as indicated in the financial report[43]

Financial Performance - The company's operating revenue for Q3 2021 was ¥187,310,939.03, representing a year-over-year increase of 16.41%[6]. - The net profit attributable to shareholders for Q3 2021 was ¥50,538,822.44, reflecting a 36.07% increase compared to the same period last year[6]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥50,707,956.42, up 39.57% year-over-year[10]. - The basic earnings per share for Q3 2021 was ¥0.13, an increase of 30.00% compared to the previous year[10]. - The diluted earnings per share for Q3 2021 was also ¥0.13, showing a 30.00% increase year-over-year[10]. - Total operating revenue for the first three quarters of 2021 reached ¥589,084,976.50, an increase of 8.4% compared to ¥543,589,063.41 in the same period of 2020[32]. - Net profit attributable to shareholders of the parent company was ¥133,515,911.70, compared to ¥140,205,001.57 in the previous year, indicating a decrease of 4.9%[35]. - The total comprehensive income attributable to the parent company was CNY 133,300,185.61, compared to CNY 139,717,478.63 in the previous year, reflecting a decrease of approximately 3%[37]. - Basic and diluted earnings per share were both CNY 0.33, down from CNY 0.39 in the same period last year, indicating a decline of about 15.4%[37]. Assets and Liabilities - The total assets at the end of the reporting period were ¥1,629,329,313.26, a 6.27% increase from the end of the previous year[10]. - The company's total assets reached ¥1,629,329,313.26, up from ¥1,533,212,830.38, reflecting an increase of 6.3%[32]. - The equity attributable to shareholders at the end of the reporting period was ¥1,471,598,682.67, reflecting a 6.23% increase compared to the previous year[10]. - The company's total liabilities increased to ¥156,141,171.78 from ¥147,980,393.32, representing a growth of 8.0%[30]. - The total non-current liabilities rose to ¥10,374,304.73 from ¥6,370,367.10, indicating a year-over-year increase of 62.9%[30]. Cash Flow - The net cash flow from operating activities for the year-to-date was ¥160,513,405.34, down 21.49% compared to the previous year[10]. - Cash inflow from operating activities totaled CNY 667,239,103.01, an increase from CNY 609,684,253.79 year-over-year, representing an increase of approximately 9.4%[41]. - Net cash flow from operating activities was CNY 160,513,405.34, down from CNY 204,441,555.50 in the previous year, showing a decrease of about 21.5%[41]. - Cash outflow from investing activities was CNY 207,506,803.35, compared to CNY 108,118,871.21 in the previous year, indicating an increase of approximately 92.2%[42]. - Net cash flow from investing activities was -CNY 166,467,535.04, worsening from -CNY 107,002,148.10 year-over-year[42]. - Cash and cash equivalents at the end of the period were CNY 502,167,844.70, down from CNY 628,936,582.36 at the end of the previous year, a decrease of about 20.1%[42]. - The company reported a net increase in cash and cash equivalents of -CNY 55,249,283.00, contrasting with an increase of CNY 369,641,764.67 in the previous year[42]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 11,650[17]. - The company has a major shareholder, Zhejiang Tongben Investment Co., Ltd., holding 38.30% of shares, and another significant shareholder, Chu Yizhou, holding 28.00%[20]. - The company has no pledged, marked, or frozen shares among its major shareholders, indicating a stable ownership structure[20]. Research and Development - Research and development expenses for the third quarter amounted to ¥40,813,549.75, compared to ¥30,955,891.67 in the same quarter last year, reflecting a significant increase of 31.9%[32]. - The company has not disclosed any new product or technology developments during the reporting period[24]. Other Information - The company reported government subsidies recognized in the current period amounting to ¥934,971.79, with a year-to-date total of ¥6,080,962.05[10]. - There are no significant mergers or acquisitions reported in the current financial period[24]. - Other comprehensive income for the period was reported at -¥217,784.10, compared to -¥487,522.94 in the previous year, showing an improvement[35]. - The company's cash and cash equivalents decreased to CNY 507.35 million from CNY 564.10 million, representing a decline of approximately 10.05%[24]. - Accounts receivable stood at CNY 140.63 million, slightly down from CNY 142.63 million, indicating a decrease of about 1.41%[27]. - Inventory increased to CNY 285.67 million from CNY 237.79 million, showing a growth of approximately 20.12%[27]. - Non-current assets totaled CNY 637.01 million, up from CNY 555.45 million, marking an increase of about 14.66%[27]. - The company reported a significant increase in other equity instrument investments, rising to CNY 15.30 million from CNY 0.30 million, a growth of 5,000%[27]. - The company's deferred income increased to ¥6,065,119.41 from ¥4,136,572.50, showing a growth of 46.7%[30]. - The company received CNY 61,637,626.09 in tax refunds, significantly higher than CNY 27,717,718.95 in the previous year, marking an increase of approximately 122%[41]. - The company paid CNY 112,243,152.30 to employees, up from CNY 80,304,762.24 in the previous year, reflecting an increase of about 39.7%[41].

Financial Performance - Aurisco reported a total revenue of RMB 150 million for the first half of 2021, representing a year-on-year increase of 25%[17]. - The company achieved a net profit of RMB 30 million, which is a 15% increase compared to the same period last year[17]. - The company's operating revenue for the first half of 2021 was ¥401,774,037.47, representing a 4.99% increase compared to ¥382,680,592.84 in the same period last year[22]. - Net profit attributable to shareholders decreased by 19.49% to ¥82,977,089.26 from ¥103,062,918.26 year-on-year[22]. - The net cash flow from operating activities fell by 32.35% to ¥88,783,067.78 compared to ¥131,237,065.89 in the previous year[22]. - Basic earnings per share decreased by 27.59% to ¥0.21 from ¥0.29 in the same period last year[22]. - The company's total operating revenue for the first half of 2021 reached ¥401,774,037.47, an increase of 5.7% compared to ¥382,680,592.84 in the same period of 2020[163]. - Total operating costs increased to ¥309,659,105.28, up 16.9% from ¥264,312,368.86 year-over-year[163]. - Net profit for the first half of 2021 was ¥82,977,089.26, a decrease of 19.5% from ¥103,062,918.26 in the previous year[165]. - The company's total comprehensive income for the first half of 2021 was CNY 64,776,820.02, down 20.6% from CNY 81,629,021.44 in the same period of 2020[173]. Market Expansion and Strategy - Aurisco plans to expand its market presence in Southeast Asia, targeting a 10% market share by the end of 2022[17]. - The company is exploring potential acquisitions in the biotech sector to diversify its product offerings and enhance its competitive edge[17]. - The company has established partnerships with domestic pharmaceutical firms, significantly enhancing its domestic market expansion efforts[47]. - The company plans to continue focusing on market expansion and new product development to drive future growth[186]. Research and Development - The company is investing RMB 20 million in R&D for new drug formulations, aiming to launch two new products by Q4 2022[17]. - R&D expenses totaled ¥27.96 million, a 30.02% increase from ¥21.51 million, reflecting the company's commitment to product diversification[48]. - Currently, the company has 26 products under development, with multiple new products expected to enter the registration application stage in the next 3-5 years[70]. - The company has established six major engineering technology innovation platforms focused on small molecule drugs, peptide drugs, and innovative drug development[40]. Environmental Responsibility - The company has established a comprehensive environmental risk emergency mechanism and has filed an emergency response plan with local environmental authorities[96]. - The company has implemented an online monitoring system for wastewater and VOC emissions, ensuring compliance with environmental standards[99]. - The company reported a total of 617.3663 tons of solid waste disposed of in the first half of 2021[82]. - The company is maintaining a safety stock of key raw materials to mitigate supply chain risks due to the pandemic[74]. - The company has upgraded its waste gas treatment facilities, reducing the number of exhaust pipes from 15 to 7, enhancing treatment capacity[91]. Financial Management and Shareholder Commitments - The company has committed to a share lock-up period from September 21, 2020, to September 20, 2023, for major shareholders and executives[108]. - The company will implement measures to stabilize stock prices if the closing price falls below the latest audited net asset value per share for 20 consecutive trading days within three years post-listing[125]. - Shareholders must publicly disclose reasons for any breach of lock-up commitments and apologize to other shareholders and the public[115]. - The company will enhance the management of raised funds and ensure their reasonable use to improve profitability and operational efficiency[128]. Operational Efficiency - The company has implemented new strategies to improve operational efficiency, projected to save RMB 5 million annually[17]. - The company completed 26 quality audits in the first half of 2021, significantly up from 11 audits in the entire year of 2020[45]. - The company has established a complete raw material drug sales system across the Americas, Europe, and Asia, collaborating with major pharmaceutical companies[44]. Financial Position - The company's net assets attributable to shareholders increased by 2.67% to ¥1,422,180,104.08 compared to ¥1,385,232,437.06 at the end of the previous year[22]. - Total assets grew by 2.17% to ¥1,566,428,798.87 from ¥1,533,212,830.38 at the end of the last year[22]. - Cash and cash equivalents decreased by 12.67% to ¥492,617,365.14 from ¥564,096,120.31 year-over-year[57]. - Accounts receivable increased by 9.30% to ¥151,501,447.77 from ¥142,628,037.16 year-over-year[57]. - Inventory increased by 12.92% to ¥268,521,526.50 from ¥237,792,190.43 year-over-year[59].

Financial Performance - Net profit attributable to shareholders of the listed company was ¥32,573,374.77, a decrease of 34.86% year-on-year[12]. - Operating income for the period was ¥186,327,671.01, reflecting a growth of 3.11% compared to the same period last year[12]. - Basic earnings per share decreased by 42.86% to ¥0.08 compared to ¥0.14 in the same period last year[12]. - The company reported a net profit after deducting non-recurring gains and losses of ¥27,091,502.56, a decrease of 40.25% year-on-year[12]. - The company reported a net profit of ¥461,623,567.05, compared to ¥429,050,192.28 in the previous period, indicating an increase of about 7.6%[33]. - Net profit for Q1 2021 was 32,573,374.77 RMB, a decrease from 50,007,600.35 RMB in Q1 2020, reflecting a decline of approximately 34.8%[45]. - Operating profit for Q1 2021 was 40,431,015.47 RMB, down from 59,261,706.40 RMB in Q1 2020, showing a decrease of around 31.8%[45]. - The total comprehensive income for the first quarter of 2021 was CNY 32,363,992.49, compared to CNY 39,986,710.95 in the first quarter of 2020, indicating a decrease[49]. Assets and Liabilities - Total assets at the end of the reporting period reached ¥1,559,949,461.59, an increase of 1.74% compared to the end of the previous year[12]. - Total liabilities amounted to ¥142,379,163.18, a decrease from ¥147,980,393.32[33]. - Total equity attributable to shareholders reached ¥1,417,570,298.41, up from ¥1,385,232,437.06[33]. - Current assets totaled ¥836,010,475.25, slightly increasing from ¥826,056,026.32[37]. - The total assets of the company were reported at ¥1,448,139,593.99, an increase from ¥1,420,402,479.45[40]. - The company's total non-current liabilities were reported at ¥6,233,471.25, down from ¥6,370,367.10[33]. Cash Flow - The net cash flow from operating activities was ¥23,534,564.69, representing a year-on-year increase of 29.44%[12]. - Cash inflow from operating activities totaled CNY 196,681,955.86, up from CNY 153,102,470.25 in the same period last year, representing a growth of approximately 28.5%[53]. - The net cash flow from operating activities was CNY 23,534,564.69, compared to CNY 18,182,099.10 in the first quarter of 2020, reflecting an increase of about 29.5%[53]. - Cash outflow from investing activities was CNY 81,367,366.02, significantly higher than CNY 50,883,658.23 in the previous year, indicating increased investment activity[53]. - The net cash flow from investing activities was -CNY 81,280,272.02, compared to -CNY 50,863,847.96 in the first quarter of 2020, showing a larger cash outflow[53]. - The cash and cash equivalents at the end of the period were CNY 497,284,564.09, down from CNY 191,638,441.57 at the end of the first quarter of 2020[55]. Shareholder Information - The total number of shareholders at the end of the reporting period was 14,621[18]. - The top ten shareholders held a total of 38.30% of the shares, with the largest shareholder holding 153,583,200 shares[18]. Expenses - Sales expenses decreased by 38.76% to ¥6,539,816.02 from ¥10,679,614.00, due to the implementation of new revenue standards[23]. - Management expenses increased by 44.29% to ¥23,845,663.71 from ¥16,526,760.47, mainly due to increased operational and environmental costs[23]. - Research and development expenses for Q1 2021 were 11,647,603.71 RMB, an increase from 9,943,504.94 RMB in Q1 2020, representing a growth of about 17.2%[42]. - Financial expenses for Q1 2021 were 1,776,525.39 RMB, compared to a financial income of -4,766,700.20 RMB in Q1 2020, indicating a significant shift in financial performance[42]. - Tax expenses for Q1 2021 were 7,600,697.70 RMB, down from 8,858,557.08 RMB in Q1 2020, indicating a decrease of about 14.2%[45]. Other Financial Metrics - The weighted average return on net assets was 2.32%, down by 2.66 percentage points from the previous year[12]. - The company’s cash and cash equivalents decreased to ¥421,008,270.54 from ¥461,238,278.85, a decline of approximately 8.5%[37]. - The company received CNY 19,388,619.25 in tax refunds, an increase from CNY 8,487,121.95 in the previous year, indicating improved cash flow management[53]. - The company paid CNY 44,557,128.93 to employees, which is higher than CNY 35,189,038.05 in the first quarter of 2020, reflecting increased operational costs[53]. - The company is focusing on expanding its market presence and investing in new technologies, as indicated by the significant cash outflows in investing activities[53].

Financial Performance - The company's operating revenue for 2020 was CNY 721,440,229.88, representing a 24.04% increase compared to CNY 581,632,761.51 in 2019[25]. - The net profit attributable to shareholders for 2020 was CNY 157,227,222.39, a decrease of 15.53% from CNY 186,130,277.81 in 2019[25]. - The net profit after deducting non-recurring gains and losses was CNY 152,038,673.07, which is a 4.10% increase from CNY 146,047,573.83 in 2019[25]. - The net cash flow from operating activities for 2020 was CNY 214,481,140.46, up 19.22% from CNY 179,903,617.01 in 2019[25]. - The total assets at the end of 2020 were CNY 1,533,212,830.38, a 39.35% increase from CNY 1,100,247,816.67 at the end of 2019[25]. - The net assets attributable to shareholders at the end of 2020 were CNY 1,385,232,437.06, reflecting a 41.74% increase from CNY 977,283,198.52 at the end of 2019[25]. - The basic earnings per share for 2020 was CNY 0.42, down 19.23% from CNY 0.52 in 2019[26]. - The weighted average return on equity for 2020 was 14.28%, a decrease of 6.81 percentage points from 21.09% in 2019[26]. Dividend Distribution - The company plans to distribute a cash dividend of RMB 1.20 per 10 shares, totaling RMB 48,120,000 based on a total share capital of 401,000,000 shares as of December 31, 2020[8]. - The cash dividend for 2019 was CNY 1.00 per 10 shares, amounting to CNY 36 million, which represented 19.34% of the net profit attributable to ordinary shareholders[147]. - The company aims to maintain a stable and continuous profit distribution policy, prioritizing cash dividends when conditions allow[145]. - The company’s profit distribution policy includes a minimum cash distribution of 20% of the available profit when there are no major investment plans[145]. Audit and Compliance - The company reported a standard unqualified audit opinion from Tianjian Accounting Firm for the fiscal year 2020[7]. - The company’s financial report has been confirmed as true, accurate, and complete by its management[5]. - The company has not violated any decision-making procedures regarding external guarantees[10]. - The company has not encountered any situations that would lead to a risk of suspension or termination of its listing[172]. - The company has not reported any significant accounting errors or changes in accounting policies that would impact its financial statements[170]. Research and Development - The company has a research and development team of 127 members, accounting for 13.53% of total employees, with 9 PhDs and 27 Master's degree holders[47]. - Research and development expenses totaled 47.35 million RMB, a 35% increase compared to the previous year, with five products successfully developed during the reporting period[56]. - The company submitted nine invention patents and received authorization for seven, totaling 15 valid patents by the end of the reporting period[56]. - The company has completed R&D for 5 products and has 16 products currently under development, with 127 R&D personnel including 9 PhDs[103]. - The company’s R&D investment amounted to 47.35 million RMB, accounting for 6.56% of operating revenue, with a year-on-year growth of 34.91%[108]. Market and Sales - The global pharmaceutical market is projected to exceed 1.5 trillion USD by 2023, with an annual growth rate of 4%-5%[40]. - In 2020, the revenue of China's pharmaceutical manufacturing industry was 2.48573 trillion RMB, with a year-on-year growth of 4.5%[41]. - The company has established a comprehensive sales system for APIs in the Americas, Europe, and Asia, with stable long-term partnerships with major pharmaceutical companies[49]. - The company’s major sales model is direct sales, primarily targeting formulation production enterprises, with a stable customer base established through long-term cooperation[111]. - The company’s overseas sales accounted for 96% of its main business revenue, highlighting its reliance on international markets[136]. Environmental Responsibility - The company is classified as a key pollutant discharge unit by environmental protection authorities[188]. - Wastewater discharge amounted to 71,000 tons, with actual COD emissions of 2.13 tons and ammonia nitrogen emissions of 0.11 tons[189]. - VOCs emissions from waste gas were recorded at 36.48 tons, with actual emissions of 0.999 tons[189]. - The company implemented a new RTO facility with a capacity of 20,000 m³/h for waste gas treatment, which is currently operational[194]. - The company has established a comprehensive environmental risk emergency mechanism and updated its emergency response plan for pollution incidents[198]. Corporate Governance - The company has committed to a lock-up period for major shareholders, lasting from September 21, 2020, to September 20, 2023, during which they cannot transfer or manage their shares[151]. - Shareholders are required to maintain a minimum selling price for their shares after the lock-up period, which cannot be lower than the adjusted issuance price[152]. - The company will publicly disclose any failure to adhere to lock-up commitments and will apologize to shareholders, with penalties including extending the lock-up period[157]. - The company has established long-term commitments regarding share transfers for its major shareholders, ensuring compliance with relevant regulations[154]. - The company has made commitments to ensure the accuracy and completeness of its IPO prospectus, taking legal responsibility for any misstatements[168].

Financial Performance - Net profit attributable to shareholders increased by 16.96% to CNY 140,205,001.57 for the first nine months of the year[18]. - Operating income rose by 24.24% to CNY 543,589,063.41 year-to-date[18]. - Basic and diluted earnings per share increased by 18.18% to CNY 0.39[20]. - Total operating revenue for Q3 2020 was CNY 160,908,470.57, an increase from CNY 150,508,283.81 in Q3 2019, representing a growth of approximately 9.3%[53]. - Net profit for Q3 2020 was CNY 37,142,083.31, compared to CNY 47,838,046.24 in Q3 2019, reflecting a decrease of approximately 22.4%[56]. - The company reported a total profit of CNY 40,556,789.44 for Q3 2020, compared to CNY 52,926,970.31 in Q3 2019, a decline of approximately 23.4%[56]. - The company’s total comprehensive income for Q3 2020 was CNY 36,394,097.68, compared to CNY 46,654,084.84 in Q3 2019, a decrease of approximately 22.0%[59]. - Total operating costs for Q3 2020 were CNY 125,000,171.74, up from CNY 100,835,768.20 in Q3 2019, indicating a rise of about 24.0%[53]. Assets and Liabilities - Total assets increased by 36.68% to CNY 1,503,826,883.82 compared to the end of the previous year[18]. - Total liabilities rose to approximately $135.70 million, up from $122.96 million, reflecting an increase of about 10.5%[42]. - The company's total liabilities increased significantly, with other payables rising by 187.04% to ¥1,950,920.93 from ¥679,675.49, mainly due to performance guarantee deposits received by a subsidiary[31]. - The company's cash and cash equivalents increased by 139.07% to ¥633,666,582.36 from ¥265,057,317.69 due to funds raised from stock issuance[31]. - Current assets reached approximately $1.01 billion, compared to $664.85 million in the previous year, marking a 52% increase[41]. - The company's construction in progress increased by 46.98% to ¥224,059,540.91 from ¥152,441,774.09, due to increased expenditures on factory construction[31]. Cash Flow - Net cash flow from operating activities increased by 57.90% to CNY 204,441,555.50 for the first nine months[18]. - Cash flow from operating activities for the first three quarters of 2020 was approximately ¥609.68 million, compared to ¥471.99 million in the same period of 2019, representing a growth of 29.1%[68]. - Total cash inflow from operating activities reached ¥442.95 million, up from ¥387.51 million year-over-year, reflecting a growth of 14.3%[75]. - Cash inflow from financing activities amounted to ¥312.28 million, with no previous year comparison available[75]. - The net cash flow from financing activities was ¥273.78 million, indicating a strong inflow compared to the previous year[75]. Shareholder Information - The company had a total of 28,438 shareholders at the end of the reporting period[26]. - The top shareholder, Zhejiang Tongben Investment Co., Ltd., holds 38.30% of the shares[26]. - Shareholders' equity attributable to the parent company increased by 39.99% to CNY 1,368,125,593.47 compared to the end of the previous year[18]. Research and Development - The company's research and development expenses rose by 78.52% to ¥30,955,891.67 compared to ¥17,340,069.60 in the previous year, primarily due to increased R&D efforts following the merger with Tianjin Aorite[33]. - The company plans to continue investing in R&D to enhance product offerings and market expansion strategies[54]. - R&D expenses for Q3 2020 amounted to CNY 9,448,721.07, an increase from CNY 5,038,679.31 in Q3 2019, showing a growth of about 87.5%[53]. Other Financial Metrics - The weighted average return on net assets decreased by 0.44 percentage points to 13.68%[20]. - The company reported a government subsidy of CNY 148,895.85 for the current period[24]. - The company's capital reserve increased by 98.46% to ¥489,874,194.71 from ¥246,832,938.71, mainly due to capital premiums from stock issuance[31]. - The company recorded a 252.02% increase in investment income to ¥1,692,036.47 from ¥480,661.45, resulting from increased financial product purchases[33]. - The company experienced a foreign exchange loss of approximately -¥567,722.65 during the reporting period[77].

Financial Performance - Net profit attributable to shareholders increased by 16.96% to CNY 140,205,001.57 for the year-to-date period[18] - Operating income rose by 24.24% to CNY 543,589,063.41 for the year-to-date period[18] - Basic earnings per share increased by 18.18% to CNY 0.39[20] - Total operating revenue for Q3 2020 was CNY 160,908,470.57, an increase from CNY 150,508,283.81 in Q3 2019, representing a growth of approximately 9.3%[53] - Net profit for Q3 2020 was CNY 37,142,083.31, compared to CNY 47,838,046.24 in Q3 2019, reflecting a decrease of approximately 22.4%[56] - The total profit for Q3 2020 was CNY 40,556,789.44, compared to CNY 52,926,970.31 in Q3 2019, reflecting a decrease of about 23.4%[56] - The company reported a comprehensive income total of CNY 36,394,097.68 for Q3 2020, down from CNY 46,654,084.84 in Q3 2019, indicating a decline of approximately 22.0%[59] Assets and Liabilities - Total assets increased by 36.68% to CNY 1,503,826,883.82 compared to the end of the previous year[18] - The total assets of the company as of the end of the reporting period were CNY 1,424,176,116.28, up from CNY 1,004,263,599.44 in the previous year, indicating a growth of approximately 41.7%[52] - Total liabilities amounted to approximately $135.70 million, an increase from $122.96 million, representing a rise of about 10.5%[42] - The company's total liabilities increased by 187.04% in other payables, amounting to RMB 1,950,920.93, due to performance guarantee deposits received by its subsidiary[31] - The company's contract liabilities reached RMB 6,616,678.80, reflecting the adjustment from previously reported prepayments under new revenue accounting standards[31] Cash Flow - Net cash flow from operating activities increased by 57.90% to CNY 204,441,555.50 for the year-to-date period[18] - Cash flow from operating activities for the first three quarters of 2020 was approximately ¥609.68 million, an increase of 29.1% from ¥471.99 million in the same period of 2019[68] - The net increase in cash and cash equivalents for the third quarter of 2020 was ¥178,654,318.97, compared to a decrease of -¥3,189,159.47 in the same quarter of 2019[77] - The ending balance of cash and cash equivalents reached ¥381,492,319.15, significantly higher than ¥144,058,177.64 at the end of the previous year[77] - Cash inflow from financing activities totaled ¥312,284,700.00, with no previous year comparison available[75] Research and Development - The company's research and development expenses rose by 78.52% to RMB 30,955,891.67 compared to RMB 17,340,069.60, primarily due to increased R&D efforts following the merger with Tianjin Aorite[33] - R&D expenses for Q3 2020 amounted to CNY 9,448,721.07, which is an increase from CNY 5,038,679.31 in Q3 2019, showing a growth of about 87.5%[53] - The company plans to continue investing in R&D to enhance product offerings and market competitiveness[54] Shareholder Information - The total number of shareholders reached 28,438[26] - The largest shareholder, Zhejiang Tongben Investment Co., Ltd., holds 38.30% of shares[26] Other Income and Expenses - The company received government subsidies amounting to CNY 148,895.85 during the reporting period[24] - The company reported a non-operating income of CNY 950,911.05 for the year-to-date period[24] - The company's financial expenses showed a significant change of -183.11%, reflecting currency exchange gains due to fluctuations in exchange rates[33] - The company's other comprehensive income showed a negative change of 57.63%, amounting to RMB -1,333,419.57, primarily due to foreign currency translation differences[31]